1. Market Research
  2. > Healthcare
  3. > Pathology
  4. > Chronic Disease Market Trends
  5. > Preventive Asthma Drug Market Outlook 2020

Preventive Asthma Drug Market Outlook 2020

  • December 2015
  • -
  • RNCOS
  • -
  • 50 pages

Asthma is showing high prevalence worldwide. About 300 Million people are suffering from asthma. This is due to continuously deteriorating air quality, which is causing several allergies. In recent years, researchers have explored wide variety of preventive drugs that can delay asthma attacks. These drugs are being highly acknowledged by the doctors and consumers. The practice of prescribing preventive drugs by doctors is gaining momentum in the US, Europe and Asia-Pacific. Foreseeing the demand, several pharma players are shifting their R&D focus towards preventive asthma drugs. Some of the leading players in the pharma industry include Glaxosmithkline, Astrazeneca, Merck, Novartis, Roche, and others. The drugs by these players contributed millions of dollars to their revenue in 2014.

In its latest research, “Preventive Asthma Drug Market Outlook 2020”, RNCOS presents a comprehensive analysis of the industry. The report covers key drivers & challenges, and trends & developments that are peculiar to the drug market. The research includes estimated market figures of 2014, and forecasted numbers till 2020. The market was estimated at US$ 22 Billion in 2014. Our analysts have segmented the preventive asthma drug industry depending on the type of drugs and geographical distribution. A separate section is allotted to the competitive landscape, including the business overview of the key players and their SWOT analysis.

Our research revealed that inhaled corticosteroids were the most popular category of preventers during 2014. Researchers are combining corticosteroids with other form of drugs, such as long acting beta agonists in a single inhaler. The so called “combination therapy” is providing several benefits over the single dose. However, the market is facing few challenges like side-effects posed by such drugs, their high cost and lack of awareness in India, China, and other Middle East & Asia-Pacific countries.

Towards the end, RNCOS has suggested some recommendations to boost the preventers market in the coming future. On the whole, the research contains exhaustive information that will help clients in formulating market strategies and assessing opportunity areas in the preventive asthma drugs industry.

Table Of Contents

Preventive Asthma Drug Market Outlook 2020
1. Analyst View
2. Research Methodology
3. Asthma - An Introduction
4. Drivers and Challenges
4.1 Drivers
4.1.1 Rising Healthcare Expenditure
4.1.2 Growing Geriatric Population
4.1.3 Increasing Prevalence of Asthma
4.1.4 Increasing RandD Driving Innovation
4.2 Challenges
4.2.1 High Cost of Drugs
4.2.2 Side Effects Caused By Drugs
4.2.3 Limited Demand from Developing Markets
4.2.4 Inadequate Awareness
5. Preventive Asthma Drugs Market Overview
6. Market Segmentation
6.1 By Type of Drugs
6.2 By Geography
7. Trends and Developments
7.1 Combined Therapy Benefitting Asthma Patients
7.2 Monoclonal Antibody: An Emerging Effective Treatment for Asthma
7.3 Asthma Tracking Tool Aiding Disease Management
8. Competitive Assessment
8.1 Market Share of Key Players
8.2 Top Selling Preventive Asthma Drugs
8.3 Profiles
8.3.1 Glaxosmithkline
8.3.2 Astrazeneca
8.3.3 Merck
8.3.4 Roche
8.3.5 Novartis
9. Recommendations

List of Figures:

Figure 3-1: Diagnostic Flow - Chart for Asthma in Clinical Practices
Figure 5-1: Global - Preventive Asthma Drugs Market (Billion US$), 2014-2020
Figure 6-1: Global - Preventive Asthma Drugs Market by Different Types of Drugs (%), 2014
Figure 6-2: Global - Preventive Asthma Drugs Market by Geography (%), 2014
Figure 8-1: Share of Major Players in Preventive Asthma Drugs Market (%), 2014
Figure 8-2: Glaxosmithkline Plc - Revenue by Geographical Regions (%), 2014
Figure 8-3: Astrazeneca - Revenue by Geographical Regions (%), 2014
Figure 8-4: Merck - Revenue by Geographical Regions (%), 2014
Figure 8-5: Roche - Revenue by Geographical Regions (%), 2014
Figure 8-6: Novartis - Revenue by Geographical Regions (%), 2014

List of Tables:

Table 8-1: Revenues of Top Selling Preventive Asthma Drugs (Million US$), 2014
Table 8-2: Glaxosmithkline Plc - Revenue by Business Segments (Billion US$), 2013 and 2014
Table 8-3: Astrazeneca - Revenue by Business Segments (Billion US$), 2013 and 2014
Table 8-4: Merck - Revenue by Business Segments (Billion US$), 2013 and 2014
Table 8-5: Roche: Revenue by Business Segments (Billion US$), 2013 and 2014
Table 8-6: Novartis - Revenue by Business Segments (Billion US$), 2013 and 2014

View This Report »

Get Industry Insights. Simply.

  • Latest reports & slideshows with insights from top research analysts
  • 24 Million searchable statistics with tables, figures & datasets
  • More than 10,000 trusted sources
24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers
Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation

  • $ 6995
  • Industry report
  • November 2016
  • by GBI Research

Frontier Pharma: Asthma Therapeutics - Cytokine and Kinase Targeted Small Molecules and mAbs Increase Pipeline Diversity and Dominate First-in-Class Innovation Summary Asthma is a chronic condition affecting ...

Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

Asthma and COPD Drugs Market - U.S. and China Industry Analysis, Size, Share, Growth, Trends, and Forecast 2016 - 2024

  • $ 5795
  • Industry report
  • October 2016
  • by Transparency Market Research

U.S. and China Asthma and COPD Drugs Market: Overview Asthma is a disease characterized by recurrent attacks of coughing, chest-tightening, breathlessness, and wheezing as the airways narrow and swell ...

Asthma - Market Insights, Epidemiology and Market Forecast-2023

Asthma - Market Insights, Epidemiology and Market Forecast-2023

  • $ 4950
  • Industry report
  • November 2016
  • by Delve Insight

Note*: This report requires 5 business days to complete. DelveInsight’s Asthma - Market Insights, Epidemiology and Market Forecast-2023” Reports provides an overview of the disease and global market ...


ref:plp2015

Reportlinker.com © Copyright 2016. All rights reserved.

ReportLinker simplifies how Analysts and Decision Makers get industry data for their business.